Cardiol Therapeutics Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRDL research report →
Companywww.cardiolrx.com
Cardiol Therapeutics Inc. , a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis.
- CEO
- David G. Elsley
- IPO
- 2019
- Employees
- 18
- HQ
- Oakville, ON, CA
Price Chart
Valuation
- Market Cap
- $145.43M
- P/E
- -5.37
- P/S
- 0.00
- P/B
- 8.06
- EV/EBITDA
- -4.90
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -229.16%
- ROIC
- -146.36%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-33,818,874 · 7.79%
- EPS
- $-0.39 · 23.53%
- Op Income
- $-34,316,296
- FCF YoY
- 4.80%
Performance & Tape
- 52W High
- $1.71
- 52W Low
- $0.88
- 50D MA
- $1.28
- 200D MA
- $1.11
- Beta
- 0.86
- Avg Volume
- 685.87K
Get TickerSpark's AI analysis on CRDL
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CRDL Coverage
We haven't published any research on CRDL yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CRDL Report →